Improved conditions for extraction and amplification of human immunodeficiency virus type 1 RNA from plasma samples with low viral load

Journal of Human Virology

Volumn 3, Issue 1, 2000, Pages 27-34

  Villahermosa, M L ^a   Thomson, M ^a   Vazquez De Parga E ^a   Cuevas, M T ^a   Contreras, G ^a   Perez Alvarez L ^a   Delgado, E ^a   Manjon N ^a   Medrano, L ^a   Najera R ^a  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Highly active antiretroviral therapy (HAART); Human immunodeficiency virus type 1; Plasma; Resistance mutation; Reverse transcriptase polymerase chain reaction; Viral load

Indexed keywords

RNA DIRECTED DNA POLYMERASE; VIRUS RNA;

ANALYTIC METHOD; ARTICLE; DIAGNOSTIC VALUE; GENE AMPLIFICATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN TISSUE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RNA ANALYSIS; VIRUS ISOLATION; VIRUS LOAD;

DNA PRIMERS; DNA, COMPLEMENTARY; DRUG RESISTANCE, MICROBIAL; HIV INFECTIONS; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; MUTATION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, VIRAL; VIRAL LOAD;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0033911875     PISSN: 10909508     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Yerly S. Presented at the Second International Workshop on HIV Drug Resistance and Treatment Strategies, Lake Maggiore, Italy, 1998.
2. Schinazi RF, Larder BA, Mellors J. Resistance table: mutations in retroviral genes associated with drug resistance. Int Antiviral News 1997;5:129-142.
3. Nájera I, Richman DD, Olivares I, et al. Natural occurrence of drug resistance mutations in the reverse transcriptase of human immunodeficiency virus type 1 isolates. AIDS Res Hum Retroviruses 1994;10:1479-1485.
4. Nájera I, Holguín A, Quiñones-Mateu ME, et al. Pol quasispecies of human immunodeficiency virus: mutations associated with drug resistance in virus from patients undergoing no drug therapy. J Virol 1995;69:23-31.
5. Hecht FM, Grant RM, Petropoulos CJ, et al. Sexual transmission of an HIV-1 variant resistant to multiple reverse transcriptase and protease. N Engl J Med 1998;339:307-311.
6. Durant J, Clevengergh P, Halfon, et al. Drug resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial. Lancet 1999;353:2195-2199.
7. Vogelstein B, Gillespie D. Preparative and analytical purification of DNA from agarose. Proc Natl Acad Sci USA 1979;76:615-519.
8. Boom K, Sol CJ, Salimans MM, et al. Rapid and simple method for purification of nucleic acids. J Clin Microbiol 1990;28:495-503.
9. Payan C, Dupre T, Belec L. Detection of hepatitis C virus RNA by a reliable optimized single-step reverse transcription polymerase chain reaction. Res Virol 1995;146:363-370.
10. Werle E, Schneider C, Renner M, Volker M, Fiehn W. Convenient single step, one tube purification of PCR products for direct sequencing. Nucleic Acids Res 1994; 22:4354-4355.
11. Moyle GJ. Current knowledge of HIV-1 reverse transcriptase mutations selected during nucleoside analogue therapy: the potential to use resistance data to guide clinical decisions. J Antimicrob Chemother 1997;40:765-777.
12. Moyle GJ. Use of HIV resistance testing in an antiretroviral-experienced woman. Medscape HIV AIDS 1999;5:2.
13. Lorenzi P, Opravil M, Hirschel B, et al. Impact of drug resistance mutations on virologic response to salvage therapy. AIDS 1999;13:F17-F21.
14. Raboud JM, Montaner JSG, Conway B, et al. Suppression of plasma viral load below 20 copies/ml is required to achieve a long-term response to therapy. AIDS 1998;12: 1619-1624.
15. Race E, Gilbert SM, Sheldon JG, et al. Correlation of response to treatment and HIV genotypic changes during phase III trials with saquinavir and reverse transcriptase inhibitor combination therapy. AIDS 1998;12:1465-1474.
16. Kempf DJ, Rode RA, Xu Y, et al. The duration of viral suppression during protease inhibitor therapy for HIV-1 infection is predicted by plasma HIV-1 RNA at the nadir. AIDS 1998;12:F9-14.
17. Eastman PS, Mittler J, Kelso R, et al. Genotypic changes in human immunodeficiency virus type 1 associated with loss of suppression of plasma viral RNA levels in subjects treated with ritonavir (Norvir) monotherapy. J Virol 1998; 72:5154-5164.
18. Montaner JS, Harris M, Mo T, Harrigan PR. Rebound of plasma HIV viral load following prolonged suppression with combination therapy. AIDS 1998;12:1398-1399.
19. Tetali S, Bakshi S, Than S, et al. Plasma virus load evaluation in relation to disease progression in HIV-infected children. AIDS Res Hum Retroviruses 1998;14:571-577.
20. Bruisten SM, Reiss P, Loeliger AE, et al. Cellular proviral HIV type 1 DNA persists after long-term RT-inhibitor therapy in HIV type 1 infected persons. AIDS Res Hum Retroviruses 1998;14:1053-1058.
21. Higgins SJ, Hames BD. RNA Processing: A Practical Approach, vol 1, The Practical Approach Series. New York: Oxford University Press, 1993:23.
22. Gomez-Cano M, Rubio A, Ruiz L, et al. Efficiency of drug resistance genotypic test in specimens with low viral load. Antiviral Ther 1999;4:123-124.